STOCK TITAN

Xeris Biopharma Holdings Inc - XERS STOCK NEWS

Welcome to our dedicated news page for Xeris Biopharma Holdings (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xeris Biopharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xeris Biopharma Holdings's position in the market.

Rhea-AI Summary
Xeris Biopharma Holdings, Inc. granted 103,000 restricted stock units to 18 new employees under its Inducement Equity Plan. The units will vest over three years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will present at the 23rd Annual Needham Virtual Healthcare Conference. The presentation by CEO Paul R. Edick aims to provide an overview of the company's innovative products. Interested parties can access the presentation on April 9, 2024, at 11:00 am Eastern Time through the investor relations page of Xeris' website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
conferences
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) achieved total revenue of over $44M in the fourth quarter, a 34% increase from the same period the prior year, and generated approximately $164M for the full year 2023, a 49% increase versus the prior year. The company ended 2023 with over $72M in cash, cash equivalents, and short-term investments, achieving cash flow positive of over $6M in the fourth quarter. Xeris entered into a worldwide license agreement for XeriJect® formulation of teprotumumab, refinanced and upsized Hayfin term loan to a lower overall cost of capital, and provided full-year 2024 guidance of total net revenue of $170M-$200M and year-end cash, cash equivalents, and short-term investments of $55M-$75M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.48%
Tags
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. secures a $215M debt facility with Hayfin Capital Management LLP, improving cost of capital and reducing borrowing interest rate. The company can draw down $15.2M to redeem outstanding convertible notes. The facility enhances Xeris' financial flexibility for business growth and operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.48%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) announced the release of its fourth quarter and full year 2023 financial results on March 6, 2024. The company will host a conference call to discuss financial and operational results, as well as provide guidance for full-year 2024. Investors can pre-register for the call and access a replay until March 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
conferences earnings
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference. CEO Paul R. Edick to provide an overview on February 13, 2024, at 10:00 am Eastern Time. Interested individuals can access the presentation on the investor relations page of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED). The agreement includes potential payments of $75 million in development and regulatory milestones, plus sales-based milestones, and escalating single-digit royalties based on future sales of TEPEZZA using the XeriJect technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.18%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) announced the grant of 130,000 restricted stock units to 18 new employees under its Inducement Equity Plan. The units will vest over three years and are subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Company XYZ (XYZ) anticipates achieving cashflow positivity in Q4, with total revenue expected to reach the upper end of the $160M-$165M range. The company also projects to end 2023 with over $72M in cash, cash equivalents, and short-term investments, surpassing its initial guidance of $65M-$70M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
none
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
Xeris Biopharma Holdings Inc

Nasdaq:XERS

XERS Rankings

XERS Stock Data

268.27M
134.19M
3.95%
44.67%
6.4%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Chicago

About XERS

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.